Phase II and III clinical trials of Tepezza shows reduction in proptosis in thyroid eye disease.- Horizon Therapeutics
Related news and insights
Horizon Therapeutics plc announced that new pooled data from the Tepezza (teprotumumab-trbw) Phase II and Phase III clinical trials are now published in The Lancet Diabetes & Endocrinology.
Horizon Therapeutics announced new Tepezza (teprotumumab-trbw) study data, including findings suggesting benefits of Tepezza in the less severe eye of patients with Thyroid Eye Disease (TED), and new data from the OPTIC 48-week follow-up study and OPTIC-X clinical trial. In patients with TED, one eye can have more severe symptoms than the other.